Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study

Masaru Seguchi; Alp Aytekin; Erion Xhepa; Michael Haude; Adrian Włodarczak; René J. van der Schaaf; Jan Torzewski; Bert Ferdinande; Javier Escaned; Juan F. Iglesias; Johan Bennett; Gábor G. Tóth; Ralph Töelg; Marcus Wiemer; Göran Olivecrona; Paul Vermeersch; Ron Waksman; Héctor M. García‐García; Michael Joner

doi:10.4244/eij-d-24-00055

Abstract

The 12-month outcomes of BIOMAG-I - the first-in-human study investigating the third-generation drug-eluting resorbable magnesium scaffold (DREAMS 3G) - showed promising results regarding clinical outcomes and late lumen loss.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Seguchi et al. (2024) studied this question.

synapsesocial.com/papers/68e59d79b6db6435875375ca https://doi.org/10.4244/eij-d-24-00055

View Full Paper

Ask AI

Bookmark

Share

Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study

Abstract

Discussion

Cite This Study

Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading